Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database

Purpose: To survey risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) practice and advice regarding hormone replacement therapy (HRT) in women with Lynch syndrome. Methods: We conducted a survey in 31 contributing centers from the Prospective Lynch Syndrome Database (PLSD), which incorporates 18 countries worldwide. The survey covered local policies for risk-reducing hysterectomy and BSO in Lynch syndrome, the timing when these measures are offered, the involvement of stakeholders and advice regarding HRT. Results: Risk-reducing hysterectomy and BSO are offered to path_MLH1 and path_MSH2 carriers in 20/21 (95%) contributing centers, to path_MSH6 carriers in 19/21 (91%) and to path_PMS2 carriers in 14/21 (67%). Regarding the involvement of stakeholders, there is global agreement (~90%) that risk-reducing surgery should be offered to women, and that this discussion may involve gynecologists, genetic counselors and/or medical geneticists. Prescription of estrogen-only HRT is offered by 15/21 (71%) centers to women of variable age range (35–55 years). Conclusions: Most centers offer risk-reducing gynecological surgery to carriers of path_MLH1, path_MSH2 and path_MSH6 variants but less so for path_PMS2 carriers. There is wide variation in how, when and to whom this is offered. The Manchester International Consensus Group developed recommendations to harmonize clinical practice across centers, but there is a clear need for more research.

[1]  D. Evans,et al.  A mismatch in care: results of a United Kingdom‐wide patient and clinician survey of gynaecological services for women with Lynch syndrome , 2020, BJOG : an international journal of obstetrics and gynaecology.

[2]  R. Manchanda,et al.  Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. , 2020, Best practice & research. Clinical obstetrics & gynaecology.

[3]  J. Pinkerton Hormone Therapy for Postmenopausal Women. , 2020, The New England journal of medicine.

[4]  S. Houterman,et al.  Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. , 2019, The Cochrane database of systematic reviews.

[5]  Aung Ko Win,et al.  Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database , 2019, Genetics in Medicine.

[6]  P. Møller,et al.  The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome , 2019, Genetics in Medicine.

[7]  A. Bats,et al.  Prophylactic hysterectomy in Lynch syndrome: Feasibility and outcomes , 2019, European Journal of Obstetrics & Gynecology and Reproductive Biology.

[8]  M. Dwyer,et al.  Genetic/Familial high-risk assessment: Colorectal, version 2.2019 featured updates to the NCCN guidelines , 2019 .

[9]  Aung Ko Win,et al.  Cancer Risks for PMS2-Associated Lynch Syndrome. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Crosbie,et al.  Recognizing Gynecological Cancer in Primary Care: Risk Factors, Red Flags, and Referrals , 2018, Advances in Therapy.

[11]  D. Evans,et al.  Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome , 2017, JAMA oncology.

[12]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[13]  P. Møller,et al.  Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.

[14]  W. Rocca,et al.  Long-term health consequences of premature or early menopause and considerations for management , 2015, Climacteric : the journal of the International Menopause Society.

[15]  E. Giovannucci,et al.  The effect of estrogen vs. combined estrogen‐progestogen therapy on the risk of colorectal cancer , 2012, International journal of cancer.

[16]  D. Winter,et al.  Oestrogen and the colon: potential mechanisms for cancer prevention. , 2008, The Lancet. Oncology.

[17]  M. Munsell,et al.  Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. , 2006, The New England journal of medicine.

[18]  Heidi D Nelson,et al.  Postmenopausal hormone replacement therapy: scientific review. , 2002, JAMA.

[19]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[20]  L. Aaltonen,et al.  Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. , 2000, Gastroenterology.

[21]  S. Shapiro,et al.  A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  F. Grodstein,et al.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. , 1999, The American journal of medicine.

[23]  V. Hasselblad,et al.  Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis , 1998, Obstetrics and gynecology.

[24]  R. Nelson,et al.  Colorectal , 1994, Current opinion in general surgery.